EZEN 10mg x 30 tabl
Primary hypercholesterolemia Ezen, administered together with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolemia who are not adequately controlled on a statin alone. Ezen as monotherapy is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolemia for whom a statin is inappropriate or not well tolerated. Prevention of cardiovascular events Ezen is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients with ischaemic heart disease (IHD) and a history of acute coronary syndrome (ACS), when added to ongoing statin therapy or initiated concomitantly with a statin. Homozygous familial hypercholesterolemia Ezen, administered together with a statin, is indicated as adjunctive therapy to diet in these patients. Patients may also benefit from other adjuvant therapeutic agents/methods (e.g. LDL apheresis). Homozygous sitosterolemia (phytosterolemia) Ezetimibe is indicated as adjunctive therapy to diet in patients with homozygous familial sitosterolemia. Ezetimibe 10 mg
